A Phase II, Open-Label, Controlled, Randomized Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-beta.

Trial Profile

A Phase II, Open-Label, Controlled, Randomized Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-beta.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2015

At a glance

  • Drugs CDX 1307; Cisplatin; Gemcitabine; Granulocyte-macrophage colony-stimulating factors; Poly ICLC; Resiquimod
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms N-ABLE
  • Most Recent Events

    • 28 Jul 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 06 May 2011 Planned number of patients changed from 60 to 30.
    • 06 May 2011 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top